ARTICLE | Product Development
New bar set by BioNTech, Pfizer COVID-19 vaccine could see swift influx of challengers
The strong start for COVID-19 vaccines could be quickly followed by more data as infection rates soar
November 10, 2020 2:44 AM UTC
With interim COVID-19 vaccine efficacy data from BioNTech and Pfizer outstripping the field’s expectations, the results have set a high bar for what could be a rapid wave of readouts accelerated by surges in case counts.
The data shared by BioNTech SE (NASDAQ:BNTX) and Pfizer Inc. (NYSE:PFE) Monday represent both a rising tide that lifts all boats, and a sea level change that could potentially sink other candidates. ...